Using Metformin to Prevent Leukemia in Patients with Preleukemia and Low-Risk MDS

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This pilot study evaluates the safety and feasibility of metformin in patients diagnosed with clonal cytopenia of undetermined significance (CCUS) or lower-risk myelodysplastic neoplasms (LR-MDS). The study is divided into two main work packages: one focusing on biological features relevant to MDS progression and the other assessing the effects of metformin over 12 months in up to 40 patients. Researchers will investigate various biological markers and the mechanisms through which metformin may exert its effects on these conditions.

Why it matters

Who can join: the full rules

Patients are eligible to be included in WP1 if they meet all of the following criteria:

Inclusion criteria:

* A diagnosis of:

  * LR-MDS according to the revised international prognostic scoring system (IPSS-R), i.e., very low- or low-risk disease (IPSS-R score ≤3) in addition to a bone marrow blast percentage \<5 OR
  * CCUS defined as the presence of somatic mutation(s) or cytogenetic abnormality not diagnostic of MDS or any other malignancy in the context of persistent cytopenia (\>6 months) with other common causes of cytopenia ruled out in the setting of bone marrow morphology that is not diagnostic of MDS or any other malignancy, and hematolytic conditions have been ruled out. Peripheral blood cytopenia is defined as hemoglobin (hgb) \<11.3 g/dL (7 mmol/L) in women and hgb \<12.9 g/dL (8 mmol/L) in men, platelet count \<150 x 109/L, or neutrophil count \<1.8 x 109/L
* Menopause, if being a female, defined as females \>45 years of age who have experienced amenorrhea for minimum 12 months, without any other obvious pathological or physiological cause
* ≥18 years of age
* Written informed consent
* Willingness to comply with mandatory aspects of the protocol
* Ability to swallow pills

Exclusion criteria:

* Any prior treatment with metformin
* A diagnosis of diabetes mellitus
* Therapeutic radiation, immunosuppressive therapy (with the exception of corticosteroids), or chemotherapy within the past year
* Treatment with granulocyte colony-stimulating factor within the past 30 days
* Prior therapy with hypomethylating agents (i.e., azacitidine, decitabine)
* eGFR \<45 mL/min
* Performance status according to the Eastern Cooperative Oncology Group \>2
* Other active malignancy within the past five years
* Uncontrolled comorbidity including impaired hepatic function (total serum bilirubin \>1.5 × upper limit of the normal range (ULN), serum alanine transaminase \>3 × ULN), chronic hepatitis with decompensated cirrhosis, disabling psychiatric disease, severe neurologic disease, uncontrolled metabolic disease, or severe cardiac disease (NYHA class 3-4)

An eGFR calculation performed up to one month prior to inclusion may be used to assess renal function. If such an assessment is not available, it is performed at screening.

Healthy volunteers are eligible to be included in WP0 if they meet all of the following criteria:

Inclusion criteria:

* Healthy individuals matched on age, sex, and BMI, if possible, to individual patient participants in WP1
* Written informed consent
* Willingness to comply with mandatory aspects of the protocol

Exclusion criteria:

* Use of metformin within the past 3 years
* A diagnosis of diabetes mellitus, rheumatological disorders, autoimmune diseases or other inflammatory disorders, celiac disease, inflammatory bowel disease, or other gastrointestinal disorders or symptoms
* Treatment with immunosuppressive drugs (with the exception of corticosteroids) or chemotherapy within the past year or antibiotics within the past 6 months
* Any contraindications to MRS

Where it's running

• Rigshospitalet
  Copenhagen, Copenhagen N, Denmark Recruiting

Study contacts

• Study coordinator: Kirsten Grønbæk, Professor, MD
• Email: Kirsten.Groenbaek@regionh.dk
• Phone: +45 35456060

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Proton total marrow irradiation before allogeneic transplant for high-risk AML or MDS

  This trial tests whether adding proton-based total marrow irradiation to standard chemotherapy conditioning before allogeneic stem cell transplant can improve outcomes for adults with high-risk or relapsed/refractory AML or MDS.

  Recruiting at 2 sites Phase 1/2 Institute of Hematology and Blood Transfusion, Czech Republic · Prague and 1 other locations · NCT07532824

• A blood test to replace bone marrow exams for diagnosing cytopenias and MDS

  This study will test whether a blood test that analyzes circulating stem and progenitor cells can diagnose MDS and other unexplained low blood counts in adults referred for a bone marrow evaluation.

  Recruiting at 2 sites Weizmann Institute of Science · San Diego, California and 1 other locations · NCT07081087

• Early treatment for high-risk Clonal Cytopenia of Undetermined Significance

  This study is testing if an early treatment with a new oral medication can help people with high-risk Clonal Cytopenia of Undetermined Significance feel better and stay healthier over three years.

  Recruiting Early Phase 1 Dana-Farber Cancer Institute · Boston, Massachusetts · NCT06802146

• Oral arsenic trioxide plus vitamin C with low-intensity therapy for TP53-mutated AML/MDS/CMML

  This trial will test whether taking oral arsenic trioxide with vitamin C plus a low-intensity drug (a hypomethylating agent, with or without venetoclax) helps adults with TP53-mutated AML, MDS, or CMML who are newly diagnosed or have relapsed/refractory disease.

  Recruiting Phase 2 The University of Hong Kong · Hong Kong · NCT06778187

• Exercise for patients with low-risk myeloid cancers

  This study is testing if a special exercise program can help people with low-risk myeloid cancers stay healthy and possibly prevent their condition from getting worse.

  Recruiting Copenhagen University Hospital, Rigshospitalet · Copenhagen, Denmark and 1 other locations · NCT06773871

• Testing BH-30236 for relapsed or refractory acute myelogenous leukemia and higher-risk myelodysplastic syndrome

  This study is testing a new drug called BH-30236 to see if it can help adults with relapsed or hard-to-treat acute myelogenous leukemia or higher-risk myelodysplastic syndrome.

  Recruiting at 13 sites Phase 1 BlossomHill Therapeutics · Duarte, California and 12 other locations · NCT06501196

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.